Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the potential for combining PROTACs with other therapeutic modalities in drug discovery and reports no clinical results.

This study found that colorectal cancer patients could be categorized into two groups based on mitochondrial-related gene features, with distinct survival outcomes and tumor microenvironment characteristics, suggesting these features could inform individualized treatment plans.

In this study, researchers observed that dormant TRP-2+ melanoma cells in bone marrow can interact with CD8+ T cells in tumor-bearing ret transgenic mice, potentially influencing immune responses.

This systematic review found that toluidine blue may be valuable for diagnosing and treating specific skin tumors in the context of Mohs micrographic surgery, though literature on its use is limited and mostly qualitative.

This review highlights the potential of PROTAC technology in drug discovery for previously undruggable targets, particularly in cancer therapy, while emphasizing the urgent need to discover more E3 ligase recruiters to optimize targeted protein degradation.

This review highlights recent advancements in using nanotechnology to improve the function and delivery of PROTAC drugs, despite existing challenges like low solubility and poor permeability, aiming to enhance their potential in disease treatment.

This study found that three protocols for generating Titan cells in vitro from Candida neoformans vary in their kinetics and transcriptomic profiles, pointing to differences which could impact further research.

This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.

The authors concluded that antibodies against tyrosinase and gp100 may be effective in diagnosing melanoma, including challenging variants like amelanotic and desmoplastic types, when appropriate antigen retrieval techniques are used.

This case report details a patient with myasthenia gravis and a malignant thymoma whose rising liver function tests, initially thought to be related to antibiotic use, were ultimately attributed to thymoma-associated multiorgan autoimmunity.

This study found that TPA treatment transiently induces high levels of ODC in mouse epidermal cells, particularly around hair follicles, with localization reduced by retinoic acid or cycloheximide pretreatment.

This study developed a multifunctional hydrogel, QTMP-Gel, which significantly accelerated wound healing in an oral mucositis hamster model by providing antioxidant and antibacterial effects, reducing inflammation, and controlling infection.

This study found that the overexpression of the lncRNA HOTTIP in glioma cells increased resistance to the chemotherapy drug temozolomide, suggesting a key role for miR-10b and EMT processes in this resistance.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This review examines the development and challenges of using PROTACs, a targeted protein degradation strategy, to treat cancer by degrading specific proteins like PARPs and GPX4, highlighting issues such as target diversification and bioavailability.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This study demonstrated that in a mouse melanoma wound model, the MQ Microneedles effectively managed ROS levels to inhibit tumor growth and promote wound healing through light-controlled release.

This review highlights the potential of transcranial photobiomodulation (tPBM) as a non-invasive and affordable treatment for brain diseases, summarizing recent advances and successful protocols based on over two decades of research.

In this study, researchers described ONCO-NK-TRANSITION-GM1, a cancer therapy that's manufacturable with current pharmaceutical methods, showing a 60-80% complete response rate across various cancer types and costing $50 per dose, providing a more accessible alternative to existing treatments.

This study developed a multifunctional TA-MoS2-SF hydrogel for diabetic ulcer treatment, demonstrating enhanced photothermal bactericidal effects, immune environment remodeling, and fibroblast proliferation, suggesting it may serve as an effective 'antibacterial-immunomodulatory-repair' strategy.

This study demonstrated that a single multimode fiber can be used for single-shot wide-field reflectance imaging, achieving high correlation with the ground truth and enabling real-time microendoscopy at up to 180 frames per second.

FDG PET/CT can improve cancer treatment plans in dogs.

Recognizing minor skin lesions can help identify serious cancer syndromes.

In this experimental study, researchers found that intravitreal injections of up to 100μg of topotecan in rabbits caused no systemic or ocular toxicity, while 200μg doses resulted in localized retinal changes and decreased electroretinography amplitudes near the injection site.

This study developed the TLMG hydrogel, a seamless in situ biointerface platform, demonstrating robust adhesion, high conductivity, and therapeutic effects for intelligent wound management in complex animal models and human tests, indicating its promise for integrated bioelectronic medicine.

In this study, a patient with Cronkhite-Canada syndrome complicated by severe sepsis and disseminated intravascular coagulation was successfully treated using combined therapies, including recombinant human soluble thrombomodulin, despite the absence of a standard treatment regimen for CCS.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.